stockrowIonis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.
- Revenue
- −40.7%
- EPS
- −188.5%
- Free cash flow
- +299.3%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow IONS
Alert me
Ionis Pharmaceuticals, Inc. (IONS) Revenue
Ionis Pharmaceuticals, Inc.'s revenue for fiscal 2025 was $943.7M, up 33.8% from $705.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was $874.1M. Over the past ten years it has ranged from $283.7M (fiscal 2015) to $1.1B (fiscal 2019); the current reading is higher than 91% of that period. Ionis Pharmaceuticals, Inc. ranks 29th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $943.7M | 33.83% |
| FY2024 | $705.1M | (10.48%) |
| FY2023 | $787.6M | 34.10% |
| FY2022 | $587.4M | (27.53%) |
| FY2021 | $810.5M | 11.13% |
| FY2020 | $729.3M | (35.04%) |
| FY2019 | $1.1B | 87.20% |
| FY2018 | $599.7M | 16.63% |
| FY2017 | $514.2M | 37.93% |
| FY2016 | $372.8M | 31.40% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $267.9M | 8.88% |
| Mar 2026 | $246.1M | 21.03% |
| Dec 2025 | $203.3M | 29.74% |
| Sep 2025 | $156.7M | (65.33%) |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| IONS Ionis Pharmaceuticals, Inc. | $874.1M |
| AXSM Axsome Therapeutics, Inc. compare | $865.3M |
| MIRM Mirum Pharmaceuticals, Inc. compare | $670.8M |
| LGND Ligand Pharmaceuticals Incorporated compare | $253.8M |
| CGON CG Oncology, Inc. compare | $6.2M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| IMVT Immunovant, Inc. compare | — |
| ORKA Oruka Therapeutics, Inc. compare | — |
| KOD Kodiak Sciences Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on IONS
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement